Sangel Capital

Yiyao Technology is a drug development company with throughput screening, CADD to data, and AI-driven strategies that possess the premise of intelligence.

SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.

Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.

Aucta Pharmaceuticals is a Shanghai-based company that specializes in researching and developing pharmaceutical drugs aimed at improving drug delivery and enhancing label effectiveness. With an additional office in Princeton, New Jersey, Aucta focuses on creating novel and niche generic medical products using a drug development platform characterized by poorly water-soluble formulations and controlled release mechanisms. The company primarily targets central nervous system and oncology compounds, allowing pharmaceutical partners to develop drugs that better align with patient compliance needs. Through its innovative approach, Aucta Pharmaceuticals aims to advance the development and commercialization of branded specialty products and niche generics in the pharmaceutical industry.

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology. The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP) technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.

3D Medicines, we use individual’s genetic information to prevent, diagnose, and treat cancer. We develop personalized medicines according to target population’s genetic background, to increase efficacy and safety.

Virogin Biotech Ltd. ("Virogin") was founded in 2015, with the headquarters located in Vancouver, Canada. They are dedicated to developing the next generation of oncolytic virus (OV) therapeutics using their novel Synerlytic™ technical platform for improved cancer treatment. By exploring innovative approaches to immunotherapy, Virogin is committed to becoming a world leader in the field of immuno-oncology.

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

BrainNow is an innovative company dedicated to the field of neuromedical imaging. The core is to develop and popularize computer cloud computing tools suitable for clinical applications based on advanced computer medical image analysis technology for the auxiliary diagnosis of neurological diseases. Intelligent identification and analysis of neuroimaging images provides objective evidence for early screening and differential diagnosis of neurodegenerative diseases, and improves the accuracy and efficiency of clinical diagnosis and treatment.

Magpie Pharmaceuticals specialize in the research and development of first-in-class drugs. The company focuses on the structural modification and transformation of active natural product monomers in traditional Chinese medicines (TCM), as well as small molecular compounds currently in clinical use.

Huidu Medical provides development of gene detection methods and bioinformatics algorithms for cancer diagnosis and monitoring, and promotes the development of tumor diagnosis and treatment through our technology.

Quantapore is a biotech company developing nanopore-based nucleic acid sequencing technology. Unlike other nanopore approaches, Quantapore utilizes an optical read out which results in lower cost and higher throughput compared to electrical data acquisition. Its novel proprietary DNA sequencing technology is based on an optically labeled nanopore which interacts via energy transfer with a labeled nucleic acid sample. The quantum-optic interaction between the nanopore and the DNA allows for single molecule nucleic acid sequencing at an unprecedented speed and cost. Quantapore was founded by Sascha C. Dennstedt and Martin Huber in 2009.

Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology. The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP) technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.

Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function.

Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.

KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs.

Landing Shares is an AI-driven med-tech firm that develops artificial intelligence cervical cancer screening diagnostic technology.

Virogin Biotech Ltd. ("Virogin") was founded in 2015, with the headquarters located in Vancouver, Canada. They are dedicated to developing the next generation of oncolytic virus (OV) therapeutics using their novel Synerlytic™ technical platform for improved cancer treatment. By exploring innovative approaches to immunotherapy, Virogin is committed to becoming a world leader in the field of immuno-oncology.

Founded in 2012, Vivolight is a medical device company incubated and supported by Xi'an Institute of Optics and Precision Mechanics of Chinese Academy of Sciences. We are headquartered in Shenzhen and have established an R&D center in Xi’an. Rooted in the field of medical laser technology, we are committed to the independent development, global innovation and independent manufacturing of medical devices used for minimally invasive interventional diagnosis and treatment with the technology of laser by leveraging the world-leading photoelectric technology and combining medicine and engineering. In April 2020, our self-developed optical coherence tomography (OCT) system obtained the approval of NMPA and achieved commercialization. In December 2021, our innovative Multimodality OCT System was approved by NMPA. It is the first Multimodality OCT System in the field of coronary artery OCT that has been approved for clinical application. In the field of interventional laser therapy, we have multiple products that have entered the phase of pre-clinical study.

Virogin Biotech Ltd. ("Virogin") was founded in 2015, with the headquarters located in Vancouver, Canada. They are dedicated to developing the next generation of oncolytic virus (OV) therapeutics using their novel Synerlytic™ technical platform for improved cancer treatment. By exploring innovative approaches to immunotherapy, Virogin is committed to becoming a world leader in the field of immuno-oncology.

Founded in 2012, Vivolight is a medical device company incubated and supported by Xi'an Institute of Optics and Precision Mechanics of Chinese Academy of Sciences. We are headquartered in Shenzhen and have established an R&D center in Xi’an. Rooted in the field of medical laser technology, we are committed to the independent development, global innovation and independent manufacturing of medical devices used for minimally invasive interventional diagnosis and treatment with the technology of laser by leveraging the world-leading photoelectric technology and combining medicine and engineering. In April 2020, our self-developed optical coherence tomography (OCT) system obtained the approval of NMPA and achieved commercialization. In December 2021, our innovative Multimodality OCT System was approved by NMPA. It is the first Multimodality OCT System in the field of coronary artery OCT that has been approved for clinical application. In the field of interventional laser therapy, we have multiple products that have entered the phase of pre-clinical study.

Baolaitong provides pharmacy benefit management, pharmaceutical assistance programs, academic promotion service platforms, data analysis service systems, and out of hospital distribution management systems. Their customers inquiries are addressed by phone, address, and email.

Science For Life offers telemedicine solutions and services. They work on product development, program design, project construction, technical support, and service operations in the field of telemedicine. Their solutions include two way referral, post-hospital follow-up, remote monitoring, mobile medical, and teleconsultation.

Green Path Technology is a design and research company. It provides product quality, environmental protection regulation research, and ecological management system development solutions. Their services include consultation, substance information identification, quality and environmental solutions, and SDS production. They serve the manufacturing industry.

MAXCOM is engaged in research and development, manufacture, and sales of hematology.